Atty. Dkt. No. 081356-0251



UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Takashi ISHIHARA

Title:

PURIFICATION OF HUMAN MONOCLONAL ANTIBODY

AND HUMAN POLYCLONAL ANTIBODY

Appl. No.:

10/551,182

371(c) Date:

9/29/2005

Examiner:

Unassigned

Art Unit:

Unassigned

Confirmation Number:

Unassigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR §1.56

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56.

A copy of each non-U.S. patent document and each non-patent document is being submitted to comply with the provisions of 37 CFR §1.97 and §1.98.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

TIMING OF THE DISCLOSURE

The listed documents are being submitted in compliance with 37 CFR $\S1.97(b)$, before the mailing date of the first Office Action on the ments.

RELEVANCE OF EACH DOCUMENT

All of the documents are in English.

Applicant respectfully requests that each listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

Although Applicant believes that no fee is required for this Request, the Commissioner is hereby authorized to charge any additional fees which may be required for this Request to Deposit Account No. 19-0741.

Respectfully submitted.

Date (3 June 2006

FOLEY & LARDNER LLP Customer Number: 22428

Telephone: (202) 672-5404 Facsimile: (202) 672-5399 Stephen A. Bent Attorney for Applicant Registration No. 29,768

MODIFIED PTO/SB/08 (08-00) Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE ond to a collection of information unless it contains a valid OMB control number. Substitute for form 1449B/PTO Complete if Known INFORMATION DISCLOSURE 100 E 1 NUL Application Number 10/551,182 STATEMENT BY APPLICANT Plog Date 09/29/2005 Takashi ISHIHARA ** Named Inventor Date Submitted: June 13, 2006 Spoup Art Unit Unassigned SAN TA TRADE (use as many sheets as necessary) Examiner Name Unassigned 081356-0251 Sheet 1 of Attorney Docket Number

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No.!	U.S. Patent Document		Name of Patentee or Applicant of Cited	Date of Publication of	Pages, Columns, Lines, Where Relevant Passages or Relevant
		Number	Kind Code ² (#	Document	Cited Document MM-DD-YYYY	Figures Appear
/D.S./	C1	5 429 746		SHADLE et al.	7/4/1995	
/D.S./	C2	5 118 796		PRIOR et al.	6/2/1992	

di kerdua di ja						FOREIGN PATENT DOCUMENTS			
	Examiner Initials*	Cite No.1	Foreign Patent Document Office ³ Number ⁴ Kind Code ⁵ (if known)		Kind Code ⁵	Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Le
J	***************************************	-(-)	-EP	0-530-447		BIOTEST PHARMA CHBIL	3/10/1003		
ı	/D.S./	C4	wo	02/22079	A	ATOPIX PHARMACEUTICALS CORP et al.	3/21/2002		
۱									

Examiner Initials*	Cite No.1	NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc,) date, page(s), volume-issue number(s), publisher, city and/or country where published.	Je
/D.S./	C5	RL FAHRNER et al., "Performance comparison of Protein A affinity-chromatography sorbents for purifying recombinant monoclonal antibodies", BIOTECHNOLOGY AND APPLIED BIOCHEMISTRY, vol. 30. no. 2, 1999, pp. 121-128.	
			t

1	Examiner Signature	/David Saunders/	Date Considered	05/06/2008

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant.

Unique citation designation number. See attached Kinds of U.S. Patient Documents. *Enter Office that issued the document by the Workelster Code (WIPO Standard ST.3).** For Japanese patient documents, the indication of the year of the reigh of the Emperor must precede it enumber of the patient document. **Vind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. **Applicant is to place a check mark here if English language Translation is attached.**

Burden Hour Stalement: This form is estimated to take 2.0 hours to compete. Time will expressed upon the meets of the inclodual case. Any comments on the control of the inclodual case. Any comments on the control of the inclodual case. Any comments on the control of the inclodual case. Any comments on the control of the inclodual case. Any comments of the inclodual case. Any case of the inclodual case of the inclodual case. Any case of the inclodual case of the inclodual case. Any